It’s funny how sometimes there are many new articles about one general topic like this week with heritable (and somatic) human CRISPR gene editing and related tech. There are clear reasons for optimism in the somatic arena given advancing trials. Germline editing remains highly questionable in my view even just technically. Then there are loads […]
Weekly reads: human CRISPR, MRT risks, private IRBs, skincare Read More »
I’m sure many of you remember He Jiankui, the guy who made CRISPR babies. He ended up serving three years in jail in China. He seems to be trying for something of a comeback since his release. Were He Jiankui invitations a mistake? Some prestigious places have even invited him to give talks, which seemed
Weekly reads: He Jiankui disappoints, ALS, Vor Biopharma Read More »
Near-billionaire Bryan Johnson apparently does not like getting old and he’s trying to do something transformative about it. He and his team are experimenting in a big way. As a 55-year-old myself, I can’t blame him for wanting to fight aging in general. However, his anti-aging project includes some extreme stuff. Will some in the
Skepticism on the Bryan Johnson anti-aging extravaganza Read More »
It’s always exciting when your lab has a new paper and my team just published a study knocking out the H3f3a gene in mice, which codes for histone H3.3 protein. We found that loss of this gene leads to lethality at a late stage of embryonic development. There were also indications of more specific phenotypes
Weekly reads: H3.3 on the brain, Texas bill, HSCs Read More »
The FDA seems oddly slow in oversight of unproven stem cell clinic-related firms like one here in California called Invitrx Therapeutics. I’ve written before about Invitrx, but interactions between them and the FDA have continued including a new warning letter. It’s become a puzzling situation. More broadly, the FDA has done relatively little in the past
3rd Invitrx warning highlights FDA oversight weakness Read More »
I tend to perhaps over-focus on human CRISPR or gene editing, but other applications including in agriculture are definitely going to be huge. CRISPR in agriculture One that I’ve been following for a long time is the use of CRISPR to prevent cows from growing horns. Why is that a big deal? Just in the
Weekly reads: CRISPR chicks, HSCs, sequencing Mendel Read More »
It’s that time of year again when I grade my previous year’s predictions for the stem cell & regenerative medicine space. Overall, I did better than a typical year. I give the 2022 predictions an A- overall. This exercise can be kind of fun but also humbling. For example, I tend to be too optimistic
Grading my 2022 regenerative medicine predictions Read More »
There have been rare instances like with scientist James Wilson where researchers were involved in what I would call major misconduct but somehow managed to bounce back. In a sense, they were given second chances in part by regulators but also by other scientists or supporters. However, after extraordinary misconduct, especially contributing to the death
2nd chances after big misconduct? He Jiankui, James Wilson, others Read More »
Something called a P shot has sparked interest from some men interested in high-risk attempts at enhancement. The goal of today’s review post is to fact-check P shots. They’re sold for supposed penis enhancement or to address erectile dysfunction (ED). I’ll also fact-check so-called O shot stabs at vaginal rejuvenation or enhancement. These are both
Reviews of P shot & O shot stabs at sexual enhancement Read More »
I wrote recently about how political pressure on FDA Commissioner Stephen Hahn in 2020 may have helped the Texas firm Direct Biologics move their product ExoFlo forward inside the agency. Today I analyze the ExoFlo Phase I clinical trial paper used in that push on Hahn to get the firm the IND for a Phase II
Review of ExoFlo paper used to push Direct Biologics IND inside FDA finds red flags Read More »